Alteration in fasting glucose after prolonged treatment with a thiazide diuretic

Alteration in fasting glucose after prolonged treatment with a thiazide diuretic
Diabetes Research and Clinical Practice, 05/02/2014 Clinical Article  Clinical Trial Below

Karnes JH, et al. – The results indicate that prolonged thiazide treatment duration is associated with increased FG and that overall glycemic status worsens when thiazide/thiazide–like diuretics are combined with β blockers.
Methods

• The authors conducted an observational, non–randomized, open label, follow–up study of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR–2 studies.
• They enrolled previous participants from the PEAR or PEAR–2 studies with at least 6 months of continuous treatment with either hydrochlorothiazide (HCTZ) or chlorthalidone.
• Linear regression was used to identify associations with changes in FG after prolonged thiazide and thiazide–like diuretic treatment.

Results

• A total of 40 participants were included with a mean 29 (range 8–72) months of thiazide treatment.
• FG increased 6.5 (SD 13.0) mg/dL during short–term thiazide treatment and 3.6 (SD 15.3) mg/dL FG during prolonged thiazide treatment.
• Increased FG at follow–up was associated with longer thiazide treatment duration (β=0.34, p=0.008) and lower baseline FG (β=–0.46, p=0.02).
• β blocker treatment in combination with prolonged thiazide diuretic treatment was also associated with increased FG and increased 2–h glucose obtained from OGTT.